Immunocore (IMCR) Competitors $32.99 +0.22 (+0.67%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$32.96 -0.04 (-0.11%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMCR vs. RVMD, GRFS, TGTX, NUVL, CRSP, RYTM, LNTH, AXSM, TLX, and PCVXShould you be buying Immunocore stock or one of its competitors? The main competitors of Immunocore include Revolution Medicines (RVMD), Grifols (GRFS), TG Therapeutics (TGTX), Nuvalent (NUVL), CRISPR Therapeutics (CRSP), Rhythm Pharmaceuticals (RYTM), Lantheus (LNTH), Axsome Therapeutics (AXSM), Telix Pharmaceuticals (TLX), and Vaxcyte (PCVX). These companies are all part of the "pharmaceutical products" industry. Immunocore vs. Its Competitors Revolution Medicines Grifols TG Therapeutics Nuvalent CRISPR Therapeutics Rhythm Pharmaceuticals Lantheus Axsome Therapeutics Telix Pharmaceuticals Vaxcyte Immunocore (NASDAQ:IMCR) and Revolution Medicines (NASDAQ:RVMD) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership. Is IMCR or RVMD more profitable? Revolution Medicines has a net margin of 0.00% compared to Immunocore's net margin of -6.48%. Immunocore's return on equity of -5.86% beat Revolution Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Immunocore-6.48% -5.86% -2.09% Revolution Medicines N/A -37.06%-32.84% Do analysts recommend IMCR or RVMD? Immunocore presently has a consensus price target of $58.89, indicating a potential upside of 78.51%. Revolution Medicines has a consensus price target of $68.91, indicating a potential upside of 88.12%. Given Revolution Medicines' stronger consensus rating and higher probable upside, analysts plainly believe Revolution Medicines is more favorable than Immunocore.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunocore 1 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.55Revolution Medicines 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals believe in IMCR or RVMD? 84.5% of Immunocore shares are owned by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are owned by institutional investors. 10.4% of Immunocore shares are owned by insiders. Comparatively, 8.2% of Revolution Medicines shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more volatility and risk, IMCR or RVMD? Immunocore has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500. Comparatively, Revolution Medicines has a beta of 1.16, meaning that its stock price is 16% more volatile than the S&P 500. Which has higher valuation & earnings, IMCR or RVMD? Immunocore has higher revenue and earnings than Revolution Medicines. Immunocore is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunocore$310.20M5.34-$51.09M-$0.43-76.72Revolution Medicines$11.58M589.21-$600.09M-$4.00-9.16 Does the media prefer IMCR or RVMD? In the previous week, Revolution Medicines had 2 more articles in the media than Immunocore. MarketBeat recorded 6 mentions for Revolution Medicines and 4 mentions for Immunocore. Revolution Medicines' average media sentiment score of 1.09 beat Immunocore's score of 0.87 indicating that Revolution Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunocore 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Revolution Medicines 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryRevolution Medicines beats Immunocore on 10 of the 16 factors compared between the two stocks. Get Immunocore News Delivered to You Automatically Sign up to receive the latest news and ratings for IMCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMCR vs. The Competition Export to ExcelMetricImmunocoreMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.65B$3.00B$5.49B$9.52BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-76.7217.6228.7823.81Price / Sales5.34179.21372.2066.04Price / CashN/A41.9535.4557.96Price / Book4.588.508.275.54Net Income-$51.09M-$55.06M$3.25B$259.28M7 Day Performance-6.20%-3.99%-3.70%-4.64%1 Month Performance0.73%9.58%4.34%4.41%1 Year Performance-15.21%6.70%25.90%17.95% Immunocore Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMCRImmunocore1.7414 of 5 stars$32.99+0.7%$58.89+78.5%-16.7%$1.65B$310.20M-76.72320News CoverageUpcoming EarningsRVMDRevolution Medicines4.467 of 5 stars$37.26-1.7%$68.91+84.9%-19.1%$7.06B$11.58M-9.32250News CoveragePositive NewsUpcoming EarningsGRFSGrifols3.116 of 5 stars$10.09-0.1%$10.30+2.1%+41.1%$6.94B$7.81B8.6223,822Dividend AnnouncementTGTXTG Therapeutics4.0794 of 5 stars$35.99-2.5%$43.80+21.7%+85.0%$5.86B$329M149.96290Positive NewsUpcoming EarningsNUVLNuvalent3.2323 of 5 stars$81.94+0.7%$119.60+46.0%+2.0%$5.85BN/A-18.6740Positive NewsCRSPCRISPR Therapeutics2.8206 of 5 stars$63.75-1.6%$71.31+11.9%+2.3%$5.59B$37.31M-14.10460Upcoming EarningsAnalyst RevisionGap DownRYTMRhythm Pharmaceuticals3.5511 of 5 stars$85.68-0.9%$91.93+7.3%+88.5%$5.50B$130.13M-30.49140Upcoming EarningsInsider TradeLNTHLantheus4.6193 of 5 stars$72.41-0.7%$131.20+81.2%-28.4%$5.05B$1.53B20.57700News CoveragePositive NewsUpcoming EarningsAnalyst RevisionAXSMAxsome Therapeutics4.8236 of 5 stars$100.39-0.4%$172.33+71.7%+19.8%$4.96B$385.69M-17.40380Positive NewsUpcoming EarningsTLXTelix PharmaceuticalsN/A$13.96-1.7%$22.33+60.0%N/A$4.81B$516.72M0.00N/AGap DownPCVXVaxcyte2.2389 of 5 stars$35.87-2.1%$136.50+280.5%-58.0%$4.73BN/A-8.99160News CoveragePositive NewsUpcoming Earnings Related Companies and Tools Related Companies RVMD Competitors GRFS Competitors TGTX Competitors NUVL Competitors CRSP Competitors RYTM Competitors LNTH Competitors AXSM Competitors TLX Competitors PCVX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMCR) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunocore Holdings PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunocore With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
